Filing Flows › Comparisons › PYXS vs ABCL
Pyxis Oncology vs AbCellera Biologics: PYXS and ABCL compared
Pyxis Oncology is the larger company: $11.0M of revenue in its latest quarter (Q4 2025) against $10.6M for AbCellera Biologics (Q3 2026). Pyxis Oncology is more profitable, with an operating margin of -165.7% against -501.1%.
Where the money goes: PYXS and ABCL
Pyxis Oncology (PYXS) · Q4 2025
Pyxis Oncology, Q4 2025: revenue $11.0M, operating margin -165.7%, net loss $18.1M, operating cash flow −$10.4M. The chart follows the revenue to costs, profit and cash.
AbCellera Biologics (ABCL) · Q3 2026
AbCellera Biologics, Q3 2026: revenue $10.6M (+19% year over year), operating margin -501.1%, net loss $40.8M, operating cash flow $26.9M. The chart follows the revenue to costs, profit and cash.
| Pyxis Oncology (PYXS) | AbCellera Biologics (ABCL) | |
|---|---|---|
| Latest quarter | Q4 2025 | Q3 2026 |
| Revenue | $11.0M | $10.6M |
| Revenue growth, Y/Y | — | +19% |
| Operating margin | -165.7% | -501.1% |
| Net earnings | −$18.1M | −$40.8M |
| Net margin | -164.0% | -383.1% |
| Operating cash flow | −$10.4M | $26.9M |
| Free cash flow | — | $25.3M |
| Market value | — | $3.8B |
| Analysts’ mean target | — | $17.17 |
Where the revenue comes from
AbCellera Biologics
- Research fees: $10.5M (99%)
- Licensing and royalty revenue: $90K (1%)
Questions
Which is bigger, Pyxis Oncology or AbCellera Biologics?
Pyxis Oncology is the larger company: $11.0M of revenue in its latest quarter (Q4 2025) against $10.6M for AbCellera Biologics (Q3 2026).
Is Pyxis Oncology or AbCellera Biologics growing faster?
Pyxis Oncology is more profitable, with an operating margin of -165.7% against -501.1%.
More: Pyxis Oncology earnings · how Pyxis Oncology makes money · AbCellera Biologics earnings · how AbCellera Biologics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-K filed Mar 23, 2026; 10-Q filed Nov 9, 2026). Fiscal quarters can end on different dates. Not investment advice.